Increased Sensitivity to Interferon-α in Psoriatic T Cells
about
Wnt5a exhibits layer-specific expression in adult skin, is upregulated in psoriasis, and synergizes with type 1 interferonThe detrimental effects of IFN-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction.Type I interferon: potential therapeutic target for psoriasis?IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF).A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNsProgrammed cell death-10 enhances proliferation and protects malignant T cells from apoptosis.Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases.Biological therapy for dermatological manifestations of inflammatory bowel diseaseThe type I interferons: Basic concepts and clinical relevance in immune-mediated inflammatory diseases.STAT2 is involved in the pathogenesis of psoriasis by promoting CXCL11 and CCL5 production by keratinocytes.Update on psoriasis immunopathogenesis and targeted immunotherapy.STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma.Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma.Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases.Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling.Immune functions and recruitment of plasmacytoid dendritic cells in psoriasis.Can early treatment with biologicals modify the natural history of comorbidities?The therapeutic potential of TNF-alpha antagonists for skin psoriasis comorbidities.Investigation of latent tuberculosis infection in patients with psoriasis who are candidate for receiving immunobiological drugs.miRNA in mycosis fungoides and skin inflammation.Therapeutic potential of STAT4 in autoimmunity.Psoriatic arthritis: latest treatments and their place in therapy.Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis.STAT4 expression and activation is increased during mitosis in vitro and in vivo in skin- and mucosa-derived cell types: implications in neoplastic and inflammatory skin diseases.Vascular endothelial growth factor receptor-3 expression in mycosis fungoides.Infliximab treatment-induced paradoxical psoriasiform reaction in patient with psoriasis vulgaris showing positive lymphocyte transportation test reaction.Ubiquitin-specific protease 2 decreases p53-dependent apoptosis in cutaneous T-cell lymphoma.Keeping each other in check: a reciprocal relationship between cytokines and miRNA.Gene (mRNA) expression in canine atopic dermatitis: microarray analysis.Expression of miR-155 and miR-126 in situ in cutaneous T-cell lymphoma.STAT1 expression and activation is increased in lesional psoriatic skin.Safety of biologics in psoriasis.Paradoxical psoriasiform reactions to anti-TNFα drugs are associated with genetic polymorphisms in patients with psoriasis.Expression of chemokine receptor CXCR3 by lymphocytes and plasmacytoid dendritic cells in human psoriatic lesions.A catalog of potential putative functional variants in psoriasis genome-wide association regions.
P2860
Q24319773-5964EB11-1208-4C08-BC57-5FC6A52D0936Q30497355-953B6A5B-0932-48D5-858E-F11F6CE3C47AQ33354097-22E79AA3-30F2-47BB-AE36-122E7629B80AQ33728396-2BE9DF15-BD07-4554-A867-1E854FF65254Q34089816-A99CACA8-93A4-4B7F-A4FE-48DF73E623BCQ34154516-3FCF6162-3D17-471F-9C5A-A1D31326C38CQ34638892-3AF1E8F6-1BF2-4670-9622-B77A158B6DF3Q35058744-DE0AF0D1-AC10-434F-B8B7-5856DA3AC65EQ36338717-B4213C4B-3C88-4AF6-B9B3-2DFA9FA1B70CQ36363330-5FAA96B8-4C1B-4D02-9C38-23B122D17B6EQ36445919-F5E17DF2-17C0-4039-8F82-473B677D5FFBQ37075919-CAEF4489-FD59-4B5A-93E4-23C3DDC3044DQ37237464-0BCC5780-4E17-439C-BC03-77FFA9B8E3A8Q37299387-DFC91AD3-A8B4-429D-BA0E-78D789646CD8Q37435264-8393A178-CF31-4A9D-ADD4-BBEFA8406692Q37694579-9AFC3FD2-C976-4081-8F8C-DF9DF1BC2AE7Q37736578-ABDCA323-BAED-4BE5-A286-E4938125E59EQ37766229-47907A03-CC58-4AAC-9ECD-D5D4EC37C179Q37944171-2B9D2DF4-F126-4255-A0C3-F7ADE7D105C5Q38150868-88C0CA15-C4F4-4571-AED3-AAE03A2516E6Q38213100-053DF522-1D16-4F5E-BE0F-98FD9A9B4B7BQ38542095-55C115C7-DAF3-4349-B70D-CEBDE9A7717EQ38766379-23B2194F-2CFB-45ED-AB22-C41094CDB956Q38779319-54A6A484-DC5F-4C83-B96C-A54DB58B76B8Q39285766-815F33E1-AB7C-4ACD-ABFD-4E8C1CB03F08Q39535210-A68AE07C-3A11-4C26-8D43-123E564A6B5CQ40861722-4C750608-6B33-4419-9497-5F3C33677560Q41762770-C0816DFA-A8C9-4CDE-A45E-A5D3E3AD0B00Q42648107-173E7414-EA25-447D-943A-84F99EE06BF6Q44374191-BA0D33CC-AB94-45B3-9EC4-B4478A4F56CCQ46903707-EEB0D41A-D258-4EE6-AA20-0969365A30E7Q48144965-80462CC5-83D2-464A-A5A3-D78F523188E4Q50439934-243BEE4D-94F2-4048-9123-1EB14C2AE198Q54478104-1979BEF9-2EF4-467E-AE51-D919B771C813Q55332265-D78D5FEB-96C1-48C0-A46E-E9B8D17E1377
P2860
Increased Sensitivity to Interferon-α in Psoriatic T Cells
description
im November 2005 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 November 2005
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2005
@uk
name
Increased Sensitivity to Interferon-α in Psoriatic T Cells
@en
Increased Sensitivity to Interferon-α in Psoriatic T Cells
@nl
type
label
Increased Sensitivity to Interferon-α in Psoriatic T Cells
@en
Increased Sensitivity to Interferon-α in Psoriatic T Cells
@nl
prefLabel
Increased Sensitivity to Interferon-α in Psoriatic T Cells
@en
Increased Sensitivity to Interferon-α in Psoriatic T Cells
@nl
P2093
P50
P1476
Increased sensitivity to interferon-alpha in psoriatic T cells
@en
P2093
Karsten Wessel Eriksen
Keld Kaltoft
Niels Ødum
Paola Lovato
P304
P356
10.1111/J.0022-202X.2005.23864.X
P407
P577
2005-11-01T00:00:00Z
P5875
P6179
1047350314